Correspondence
EDITED BY LOUISE HOWARD

Contents ■ Rabbit syndrome treated with olanzapine ■ Serotonin transporters in ecstasy users ■ Substance misuse in first-episode psychosis

Rabbit syndrome treated with olanzapine

We wish to share with you our experience in treating a person with schizophrenia who developed rabbit syndrome. Rabbit syndrome, characterised by rapid, rhythmic orofacial movements, often accompanied by lip sounds (Schwartz et al, 1995) is considered one of four tardive dyskinesia (TD) variants, all of which are extrapyramidal side-effects of long-term neuroleptic treatment (Inada et al, 1991). The incidence of rabbit syndrome among TD variants is about 2.4% (Wada & Yamaguchi, 1992), with a mean prevalence of 15–20% among neuroleptic-treated patients in general (Baldessarini, 1988) and 9.9% in psychiatric hospital populations. Olanzapine is hereby suggested as a possible solution for alleviating rabbit syndrome without risking the emergence of extrapyramidal side-effects and simultaneously combating schizophrenic symptoms.

A 28-year-old single woman, suffering from schizophrenia for nine years, had been treated by depot injections of zuclopenthixol (200 mg every fortnight) and with biperiden (4 mg/day) since 1995. Her mental state deteriorated and she was hospitalised in an acute psychotic state, suffering from paranoid delusions. Signs of typical rabbit syndrome were evident.

In seeking out an appropriate treatment strategy for her psychotic state and the rabbit syndrome (which did not seem to respond to biperiden), it was decided to stop administration of zuclopenthixol and to initiate olanzapine, starting at 5 mg/day and reaching maximal dosage (10 mg/day). Within 2–3 weeks, not only had her psychotic symptoms disappeared, but improvement was also observed in her rabbit syndrome. Her Abnormal Involuntary Movement Scale (AIMS, Wojcik et al, 1980) score dropped from 14 to 8. After 25 days of hospitalisation, she was released into community care and continued to receive olanzapine (10 mg/day). Follow-up, a year later, found her to be in remission from the psychosis, with no signs of rabbit syndrome, under olanzapine treatment.

It has been postulated that the underlying mechanism of rabbit syndrome is supersensitivity of dopamine receptors, possibly due to an underlying predisposition. It has also been suggested that rabbit syndrome is a result of multiple system atrophy (Nishiyama et al, 1993). The most prominent, albeit controversial, treatment agents for rabbit syndrome are benzhexol and biperiden. We were anxious to avoid aggravation or uncovering of TD by the addition of anticholinergic agents. Olanzapine displays high affinity for type 2 serotonin (5-HT₂) receptors and, although the activity ratio between 5-HT₁ and type 2 dopamine (D₂) receptors is slightly lower than for clozapine, it is still about twice as active at 5-HT₁ than at D₂ receptors. Hence, olanzapine is less likely to be associated with TD, and its application in preventing or ameliorating rabbit syndrome seemed appropriate (O’Brien & Barber, 1998).

This case demonstrates the possible usefulness of olanzapine as a mono-drug treatment strategy for dealing with rabbit syndrome triggered by typical neuroleptics and simultaneously treating psychotic symptoms.


Serotonin transporters in ecstasy users

Semple et al (1999) report a reduction in vivo of [123I]-labelled 3β-carboxmethoxy-3-(4-iodophenyl)tropane (β-CIT) uptake in the cerebral cortex of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) users. They interpret this observation to be an indication of a decrease in serotonin transporters in the cortex of MDMA users. However, there are serious methodological concerns with this interpretation of their data.

It has been demonstrated that the radioligand [123I]-β-CIT binds with high affinity to dopamine, serotonin and noradrenaline transporters in human brain (Farde et al, 1994; Laruelle et al, 1994). In the case of the serotonin transporter, in vivo displacement of β-CIT binding by selective serotonin reuptake inhibitors (SSRIs) has established that specific (displaceable) binding occurs in brainstem and thalamus (Laruelle et al, 1993; Perker et al, 1995; Tauscher et al, 1999). However, this is not true for the cerebral cortex. Indeed, Laruelle et al (1993) observed that [123I]-β-CIT uptake in cortical areas was unaffected by citalopram administration in non-human primates. Similarly, recent SSRI displacement studies of [11C]McN-5652, a selective serotonin transporter radioligand for positron emission tomography (PET) imaging, failed to observe specific binding in the cerebral cortex (Parsey et al, 1999). The lack of evidence for specific binding to serotonin transporters in the cerebral cortex in vivo is not surprising when one considers the paucity of these transporters in primate cortex (Jagust et al, 1996). We are aware of only a single report of apparent displacement of β-CIT by citalopram in primate cortex:

R Durst, G. Katz, J. Zislin, S. Raskin, I. Kalman The Jerusalem Mental Health Center, Klar Shaul Hospital, affiliated with the Hebrew University, Hadassah Medical School, Jerusalem, 91060 Israel
a PET study of [11C]β-CIT uptake in two cynomolgus monkeys (Farde et al., 1994). However, the shape and time-scale of the binding curves for the cynomolgus monkeys are strikingly different from those observed in other non-human primate species (Laruelle et al., 1993) and in humans (Farde et al., 1994; Laruelle et al., 1994; Pirker et al., 1995). This discrepancy is particularly pronounced for the cortical curve, and one wonders to what extent these data may be relevant to human studies. Be that as it may, the bulk of the evidence indicates that serotonin transporters are present in sufficient density to be measured reliably with [123I]β-CIT only in the thalamus and brainstem, and not the cerebral cortex. The region of choice is the raphe area of the brainstem because the thalamus may have a substantial admixture of noradrenergic line transporters (Farde et al., 1994) and because it is difficult to avoid scattered radiation from the much greater accumulation of activity in the striatum in a thalamic region of interest. We have found this to be true in our studies of serotonin transporters with [123I]β-CIT, and we have observed that uptake in cortical regions does not differ significantly from the non-displaceable (non-specific) uptake seen in the cerebellum (Heinz et al., 1998). At extended times (> 4 hours post-injection in humans), when specific binding to serotonin transporters in the brainstem approaches a near-equilibrium plateau and non-specific uptake continues to washout throughout the brain, it becomes clear that cortical uptake is ‘tracking’ that of the cerebellum.

This latter point raises a further methodological concern. Semple et al. (1999) imaged [123I]β-CIT uptake at 90 minutes post-injection hoping to assess radioligand binding to serotonin transporters. However, near-equilibrium conditions for β-CIT at serotonin transporters are not established in human brain earlier than about four hours post-injection (Laruelle et al., 1994; Pirker et al., 1995). Once near-equilibrium has been established, [123I]β-CIT binding to serotonin transporters in the brainstem is quite stable and persists well into the following day (Laruelle et al., 1994; Pirker et al., 1995). Measurements at extended times of [123I]β-CIT activity in human brainstem (following decay correction and subtraction of non-specific uptake) are simply proportional to the density of serotonin transporters (Laruelle et al., 1994). Unfortunately, this is not the case for the measurements of Semple et al. (1999) at 90 minutes post-injection. At times this early, the system is not near equilibrium, and factors related to radioligand delivery and washout, rather than transporter binding per se, play a pre- valent role in determining the appearance of [123I]β-CIT images. Thus, it seems likely that factors such as blood flow, blood-brain barrier integrity, tissue permeability, etc. have confounded the cortical measurements that Semple et al. (1999) have assumed to be due to serotonin transporters.

In summary, although Semple et al. (1999) report an interesting reduction in β-CIT uptake in the cerebral cortex of MDMA users, there is no scientifically sound basis for ascribing this observation to a decrease in cortical serotonin transporters.


A. Heinz, D.W. Jones NIMH SPECT Lab., CBDB/NIMH/NIH, 10 Center Dr. Rm 4C216, Bethesda, MD 20792-1364, USA

Authors’ reply: By necessity, the discussion of methodological constraints had to be very concise in the published version of our paper (it was more detailed and included some of the arguments raised by Heinz & Jones in the originally submitted manuscript). We are therefore glad to have this opportunity to respond to the constructive comments of Heinz & Jones. They essentially make two claims: that β-CIT does not reliably label cortical serotonin transporters, so that our observed group difference must be due to an alternative mechanism; and at 90 minutes after tracer injection there is a significant admixture of other effects, such as blood flow, blood-brain barrier integrity and tissue permeability, with the same result.

The first claim is supported by some, but not all, displacement studies with SSRIs in monkeys, but inter-species comparisons of brain measures have to be judged with reserve, as Heinz & Jones point out. They also cite a very recently published abstract of a study in six humans, using an alternative (PET-) ligand. We look forward to the full paper; if the initially reported claim survives peer review, it may certainly call into question our interpretation. Moreover, it will specifically weaken the McCann et al. (1998) paper, whose authors used the same PET tracer and found cortical reductions in serotonin transporter labelling. The design of our study was based on Kuikka et al’s (1995) original report. They examined relatively large numbers of healthy volunteers (28) and patients (9) at one and two hours after injection of β-CIT. They reported significant tracer washout with 20 mg citalopram from medial prefrontal cortex (Brodmann’s area 12) in 25 subjects, 1–2 hours after injection. They also found significant specific binding of serotonin transporters in occipital cortex. Both are regions that showed activity reductions in our MDMA users. They further described reduced medial prefrontal cortex β-CIT activity at 1 hour in (alcoholic) patients compared with controls, in the absence of perfusion differences measured with the single photon emission computed tomography (SPECT) ligand 99mTc-ethyl cysteinate dimer.

The second (weaker) claim made by Heinz & Jones is correct in the sense that group differences in β-CIT binding at 90 minutes do not necessarily reflect a difference in serotonin transporter binding. However, in the absence of a priori hypotheses about generalised cell loss, reductions in blood flow, increased blood-brain barrier integrity or reduced tissue permeability,
our results are at least consistent with our interpretation. We think the writers overstate their point if they claim that at one hour non-specific factors are ‘prevalent’ in determining binding (Kuikka, 1995). Our β-CIT images clearly show activity patterns that parallel the known distribution of serotonin transporters, with relatively high activity in midbrain (Fig. 1 in Semple et al., 1999).

An important experiment that has not yet been performed is the displacement of β-CIT binding by ‘cold’ serotonin transporter ligands (e.g. citalopram) in areas that are found to be abnormal. It needs to be emphasised, however, that the more specific investigations also tend to be more invasive (e.g. PET with arterial blood sampling) or more of a burden to the subject (e.g. dynamic SPECT scan 4–24 hours after tracer injection with citalopram, resulting in corresponding increases in radiation dose or scan time). This can potentially increase measurement error and aggravate the selection bias of the study, thereby reducing its validity. What is gained in theoretical experimental power may well be lost in spurious or biased sampling, if subjects have to be paid to participate (ours were not) or if subjects are self-selected on the basis of some perceived problem. It behoves the reader to be sceptical about any claims based on small samples, as well as non-specific methodologies, and to scan the medical literature for replicable results, keeping in mind that there is publication bias in favour of positive findings. As far as MDMA-induced damage to human serotonin neurons is concerned, the jury is clearly still out.


K. P. Ebmeier, D. M. Semple, M. F. Glabus, R. E. O’Carroll, E. C. Johnstone, MRC Brain Metabolism Unit, Department of Psychiatry, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF

Substance misuse in first-episode psychosis

We read the article by Cantwell et al (1999) with interest. The study relates to an important aspect on the changing pattern of substance misuse in patients with first-episode psychosis. The authors have found that substance users were more likely to be males and to have a younger age at onset of psychosis. However, it would be more informative if the authors gave the prevalence figures in either gender and in different age groups to enable identification of high-risk groups for health promotion measures.

We would also like to highlight some discrepancies in the paper. The magnitudes of comorbid substance misuse among affective and delusional disorders have been mis-calculated in Table 2. Considering the fact that affective disorders include manic psychosis and depressive psychosis in the study, the calculated prevalence of substance misuse among affective disorders is found to be 18.9% instead of 11.9%, and for delusional disorder it is 15.4% instead of 7.7% as reported by the authors. Similarly, the total number of stimulant misusers is four, instead of three given by the authors in Table 2. Based on this newly calculated substance misuse rate, there is no significant difference in the substance misuse between people with schizophrenia (23.5%) and those with affective disorders (18.9%) ($\chi^2$=0.27, $P=0.603$). Therefore, the authors’ observation that subjects with affective disorder were less likely to be substance misusers needs to be modified.


N. Malik, M. M. Singh, S. C. Pradhan
Institute of Human Behaviour and Allied Sciences, Dilshad Garden, Delhi 110 095, India

---

One hundred years ago

**Glasgow District Asylum, Gartloch (Report for the year ending May 5th 1899)**

The average number of patients resident in the asylum during the year was 465 and comprised 236 males and 229 females. The total admissions during the year were 203 – viz., 111 males and 92 females. Of these 140 were first admissions. Dr. L. R. Oswald, the medical superintendent, states in his report that seven of those admitted were over 70 years of age, two being over 85 years. “The nursing of these old people demands the greatest care and tact, for they are specially liable to accidents by reason of their frail condition and interfering ways. They must be kept apart from the acute and excited cases.” Alcoholic inebriety is set down as having been the cause of the insanity in 50 of the persons admitted, but in many of these – as, indeed, in other cases – the illness was not due to one but to several causes, of which inebriety was the most prominent. “Intemperance, along with an enfeebled bodily condition, acting in conjunction with prolonged worry or mental strain, or following an influenza attack, but with intemperance as the main factor,” was the cause of insanity in the 50 cases referred to. General paralysis as a condition existed in 9 per cent. of the admissions, and in 16 per cent. a hereditary predisposition to insanity was established. The difficulty of obtaining reliable family histories was so great that it is considered probable that the proportion with hereditary taint was higher. During the year 98 patients were discharged as recovered, or 21 per cent. of the average population. Boarding-out, as a means of dealing with quiet and harmless cases, was largely practised during the year. 44 patients were thus sent out, but of that number seven were returned to the asylum for further
observation. The deaths during the year numbered 38, or 8 per cent. of the average number resident. Of the deaths two were attributed to senile decay, three to cerebral haemorrhage, seven to phthisis and tuberculosis, and 11 to general paralysis. There were 11 escapes during the year, seven of these being effected by patients on parole. The privilege of parole is extended to from 20 to 25 per cent. of the patients and it is much appreciated and seldom abused. Influenza visited the institution but it was not virulent; it lowered the health of many members of the staff, but was not in any case fatal. Work, especially out-of-door employment on farm and garden, for men and women has benefited many. The treatment of acute and curable cases by prolonged rest in bed has been practised with success. Recreation and treatment go hand-in-hand, the grounds adjoining the Loch affording a delightful summer resort for suitable cases. The Nurses’ Home is now well on its way to completion and it is now ready for occupation.

REFERENCE

Lancet, 18 January 1900, 124.

Researcher: Henry Rollin, Emeritus Consultant
Psychiatrist, Horton Hospital, Epsom, Surrey
Rabbit syndrome treated with olanzapine
R Durst, G. Katz, J. Zislin, S. Raskin and I. Kalman
Access the most recent version at DOI: 10.1192/bjp.176.2.193

This article cites 4 articles, 0 of which you can access for free at: http://bjp.rcpsych.org/content/176/2/193.1#BIBL

To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at /letters/submit/bjprcpsych;176/2/193

http://bjp.rcpsych.org/ on July 7, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to: http://bjp.rcpsych.org/site/subscriptions/